Adam Palermo

Adam Palermo is the Vice President of the Molecular Platform at Decibel Therapeutics, a role he held from June 2020 to December 2022. In this position, he was responsible for leading the company's platform efforts that integrated computational biology, single-cell genomics, gene therapy design, and process/analytical development to facilitate the development of new medicines for ear-related conditions. He played a significant role in driving Decibel's scientific strategy and led the initial gene therapy program, DB-OTO, which successfully reached Investigational New Drug (IND) status in 2022.1

Before his role as VP, he served as Senior Director and Head of Genomics and Computational Biology at Decibel Therapeutics from November 2018 to June 2020, and as Director of Genomics and Computational Biology from January 2016 to November 2018. Prior to joining Decibel, he held various positions at Genzyme, a Sanofi company, where he advanced through roles from Senior Scientist to Scientific Director in functional genomics.1

Palermo holds a Bachelor of Arts in Biochemical Sciences from Harvard University and a Ph.D. in Molecular Pharmacology from Stanford University, where his research focused on the genomics of stem cells and nuclear reprogramming.1